New Jersey, Nov 15, 2022: Freyr, one of the largest global Regulatory solutions and services companies, announced a new project with a Swiss-based pharma major. The project involves offering eCTD publishing services for the Australian market.
Freyr has been working with the customer on various projects along with publishing requirements. Along with our capabilities in the Regulatory space, the customer was impressed with our quick turnaround time, which was a major challenge with their internal publishing team.
“We feel proud that such an esteemed organization has trusted us with the critically important project,” said Rajiv Rangan, CEO of Freyr. “Freyr is all set to leverage next-gen technologies to support the customer’s eCTD publishing requirements and reduce its internal burden to drive its next wave of growth,” added Rajiv.
Freyr is one of the largest, global, Regulatory-focused solutions and services companies for the Life Sciences industry supporting, large, medium, and small size global life sciences companies (Pharmaceutical | Generics | Medical Device | Biotechnology | Biosimilar | Consumer Healthcare | Cosmetics) in their entire Regulatory value-chain, ranging from Regulatory Strategy, Intelligence, Dossiers, Submissions, etc. to Post-approval/Legacy Product Maintenance, Labeling, Artwork Change Management, and other related functions. Freyr is also expanding its footprint into other key areas like Pharmacovigilance.
Headquartered in New Jersey, USA, Freyr has regional offices across the UK, Germany, France, Switzerland, UAE, Canada, Mexico, Singapore, Malaysia, South Africa, Slovenia, Sri Lanka, Australia, Poland, China, Japan, and a Global Delivery Center in Hyderabad, India.
- 1100+ global customers and growing
- 1600+ in-house Regulatory experts
- 950+ in-country Regulatory affiliates across 120+ countries
- ISO 9001 Certified for strong process and quality management
- ISO 27001 Certified for information security management, state-of-the-art infrastructure